Oded Barel-Sabag

Modulight Biotherapeutics is developing a transformative optogenetic platform that precisely targets pathological neural activity when and where it occurs to restore balance in the nervous system.

🔬 Cellergy Therapeutics: Transforming Cellular Health Through Mitochondrial Innovation Our breakthrough approach harnesses the power of young, healthy mitochondria to revolutionize the treatment of degenerative and metabolic diseases. The Science Behind Our Innovation: Mitochondria - the cellular powerhouses - are essential for energy production, driving critical functions from muscle contraction to DNA repair. Yet with age, these vital organelles accumulate damage, leading to decreased cellular energy and contributing to various degenerative conditions. Our Solution: Through innovative mitochondrial transplantation therapy, we replace compromised mitochondria with fully functional ones, effectively restoring cellular energy production and enhancing cell function. Target Indications: Metabolic Disorders Type 2 Diabetes Neurodegenerative Diseases Age-related Conditions Join us as we advance this transformative technology to address critical unmet medical needs and enhance healthy longevity. #BiotechInnovation #CellularHealth #Mitochondria #DrugDevelopment #TherapeuticInnovation"

Lembas is an AI-powered bioactive discovery company pioneering the next generation of science-backed ingredients for functional foods and supplements. Our first solution GLP-1 Edge™, is a natural peptide that supports appetite regulation and metabolic health by enhancing the body’s own GLP-1 response. GLP-1 Edge™ is food-grade, clinically validated, and easy to integrate into everyday products like bars, shakes, snacks, gummies, and supplements. It works with the body, not against it, making it an ideal companion for consumers looking to manage their weight naturally, safely, and sustainably. At the core of Lembas is a proprietary AI platform that accelerates the discovery and design of targeted bioactive peptides. Backed by patent-pending university technology, Lembas is unlocking new bioactive ingredients across a broader range of health and wellbeing benefits. This is just the beginning. Stay tuned. Founded in 2024, Lembas is backed by leading investors including Flora Ventures, Bluestein, Fresh Fund, Longevity Venture Partners, Maia Ventures, Siddhi Capital, Mandi Ventures, and SDH. Our team brings deep expertise in biotech, nutrition, AI, and consumer health, with leadership experience from companies like Mondelez, PepsiCo, IFF, Brightseed, and Shiru. Backed by science. Designed for real life.

Ezra is the connective infrastructure for private credit and asset-backed finance. We help companies raising $10M–$250M+ in asset-backed and project financing connect with institutional lenders, credit funds, and broker-dealers actively deploying capital. For companies, Ezra helps structure deal materials, anticipate diligence questions, and approach investors with confidence. For lenders and intermediaries, Ezra surfaces qualified private credit opportunities and helps originate deals faster. Our team previously helped raise and deploy $15B+ in asset-backed finance at Mosaic and other companies. If youre raising capital or sourcing deals, wed love to connect.

Kimba’s technology uses AI to analyze biometric data and offer a personalized scent therapy to improve sleep and health.

Guardoc is a digital health company built by nurses for nurses that leverages AI to automate labor-intensive compliance processes typically handled by nurses. By streamlining these tasks, Guardoc increases direct patient care hours, enhances patient care and optimizes revenue management.

Remepy is Pioneering Hybrid Drugs™. Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities. Remepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities. The Digital Molecules™ enhance brain functions that balance the patients neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.

Restoring the global CO₂ balance by developing a unique marine carbon removal method that delivers optimum scale and quality at an affordable price.

The primary substance on our planet which absorbs, captures and sequesters atmospheric CO2 is water. Our technology removes CO2 from water, freeing it up to absorb more from the atmosphere, and allowing us to instantly turn any water-based infrastructure into a carbon dioxide removal facility. Our Mission Provide humanity with the technological means to create a sustainable world. Quickly, safely, and profitably. Our Solution Earth’s water sources are the most important atmospheric CO2 sink in the world. Since the industrial revolution, anthropogenic CO2 emissions have risen above the capacity of our waters to absorb them, leading to phenomena like ocean acidification, and hindering our global ecosystem’s ability to self-regulate. Our solution is to remove excess CO2 from the water and lock it away indefinitely, enhancing our planet’s ability to fight climate change by absorbing CO2 from the atmosphere. Our Technology: Marine Calcium Looping Our proprietary process utilizes calcium, one of the most abundant chemical elements on the planet, to mineralize, separate, and remove dissolved CO2 from water in a closed-loop system without further altering its chemical composition or balance in any way. This water can then be safely utilized, or returned to its source, while continuing to perform the crucial function of absorbing more atmospheric CO2 in both cases.

𝐓𝐚𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐠𝐮𝐞𝐬𝐬𝐰𝐨𝐫𝐤 𝐨𝐮𝐭 𝐨𝐟 𝐲𝐨𝐮𝐫 𝐫𝐞𝐥𝐚𝐭𝐢𝐨𝐧𝐬𝐡𝐢𝐩. OurRitual brings together compassionate human support and smart technology to help people build stronger, healthier relationships. We offer a new kind of couples therapy - one that combines expert-led care with AI-powered tools, masterclasses, and skills-based exercises to make support more personalized, proactive and accessible. Were creating a future where relational wellness is part of everyday life - not just something you turn to in crisis. If youre passionate about helping people connect, grow, and thrive, there’s a place for you here.

freshfund is a first-check VC investing in Israeli companies across segments and verticals. As one of Israels largest and most active dedicated pre-seed fund, we love to partner with founders from day-zero. Acting on high conviction and at a quick pace, we lead most of its deals, frequently collaborating with other investors to create tribes of early zealots and supporters. Check out our portfolio here >> https://www.fresh.fund/portfolio. Its never too early to have a conversation about your startup.

Modulight Biotherapeutics is developing a transformative optogenetic platform that precisely targets pathological neural activity when and where it occurs to restore balance in the nervous system.

🔬 Cellergy Therapeutics: Transforming Cellular Health Through Mitochondrial Innovation Our breakthrough approach harnesses the power of young, healthy mitochondria to revolutionize the treatment of degenerative and metabolic diseases. The Science Behind Our Innovation: Mitochondria - the cellular powerhouses - are essential for energy production, driving critical functions from muscle contraction to DNA repair. Yet with age, these vital organelles accumulate damage, leading to decreased cellular energy and contributing to various degenerative conditions. Our Solution: Through innovative mitochondrial transplantation therapy, we replace compromised mitochondria with fully functional ones, effectively restoring cellular energy production and enhancing cell function. Target Indications: Metabolic Disorders Type 2 Diabetes Neurodegenerative Diseases Age-related Conditions Join us as we advance this transformative technology to address critical unmet medical needs and enhance healthy longevity. #BiotechInnovation #CellularHealth #Mitochondria #DrugDevelopment #TherapeuticInnovation"

Lembas is an AI-powered bioactive discovery company pioneering the next generation of science-backed ingredients for functional foods and supplements. Our first solution GLP-1 Edge™, is a natural peptide that supports appetite regulation and metabolic health by enhancing the body’s own GLP-1 response. GLP-1 Edge™ is food-grade, clinically validated, and easy to integrate into everyday products like bars, shakes, snacks, gummies, and supplements. It works with the body, not against it, making it an ideal companion for consumers looking to manage their weight naturally, safely, and sustainably. At the core of Lembas is a proprietary AI platform that accelerates the discovery and design of targeted bioactive peptides. Backed by patent-pending university technology, Lembas is unlocking new bioactive ingredients across a broader range of health and wellbeing benefits. This is just the beginning. Stay tuned. Founded in 2024, Lembas is backed by leading investors including Flora Ventures, Bluestein, Fresh Fund, Longevity Venture Partners, Maia Ventures, Siddhi Capital, Mandi Ventures, and SDH. Our team brings deep expertise in biotech, nutrition, AI, and consumer health, with leadership experience from companies like Mondelez, PepsiCo, IFF, Brightseed, and Shiru. Backed by science. Designed for real life.

Ezra is the connective infrastructure for private credit and asset-backed finance. We help companies raising $10M–$250M+ in asset-backed and project financing connect with institutional lenders, credit funds, and broker-dealers actively deploying capital. For companies, Ezra helps structure deal materials, anticipate diligence questions, and approach investors with confidence. For lenders and intermediaries, Ezra surfaces qualified private credit opportunities and helps originate deals faster. Our team previously helped raise and deploy $15B+ in asset-backed finance at Mosaic and other companies. If youre raising capital or sourcing deals, wed love to connect.

Kimba’s technology uses AI to analyze biometric data and offer a personalized scent therapy to improve sleep and health.